News

Mohs Paste for Treating Melanoma: A Revival

View on the News

Consider "Paste" for High-Risk Patients

"Mohs paste is a tried and true compound that does what it's purported to do," said Dr. Kenneth Gross.

"The first patient I [used the paste on] developed a sentinel node that was swollen and large, and I thought it was a metastatic, but it turned out to be clearly an immune response. On the flip side – I don't paste everyone. But if I have a high-risk patient who is well balanced and capable of understanding the implications, I do offer to paste them."

It is important to get informed consent and explain that zinc chloride is not an approved therapy; however, assure the patient it will not interfere with any other therapy they might want to pursue. Consider reserving it for high-risk patients, many of whom have melanoma that extends to the bone. "If you do your Mohs down to the periosteum and want to know if the bone is clear, you can paste it and a day or so later the bone will decalcify and a little chip will come out and you can examine that."

Mohs paste has fallen out of use over the years as fresh-tissue surgery has gained popularity. "Fresh-tissue replaced it because it allows immediate closure, while the paste causes a lot of inflammation and, the way Dr. Mohs did it, it left a wound that healed by secondary intention. It heals well but people won’t stand for that these days." Younger physicians, he said, "want to use what’s new, and what they were taught to use."

For many years, Dr. Mohs got the paste from just one pharmacist, who retired long ago. "Then there was just no reliable place to get the stuff. But recently we've been able to work with Delasco, [a medical supply company] that can compound it very reliably. It's cheap and a small amount will last virtually forever at room temperature."

Because Mohs paste is composed of natural ingredients and has been in use for so long, it is an unpatentable therapy. Therefore, it will probably always remain on the fringes of medicine.

"You will never find any large head-to-head studies with other therapies, and no pharmaceutical company is ever going to research it. It would cost millions of dollars to do the kind of studies you’d need to get approval and then what would you have at the end? Nothing you could make money off of. So it won't happen."

Aside from some slight discomfort and the inflammatory reaction, however, there are few down sides to using the paste. "If you look at it from a perspective of what can I do that won't hurt my patients, probably helps them, and won’t interfere with definitive, modern therapy, I would say Mohs paste is a shining example."

Kenneth Gross, M.D., was a course

director at the meeting, and is a surgical dermatologist in San Diego.

He reported having no relevant conflicts of interest.



 

EXPERT ANALYSIS FROM A MEETING SPONSORED BY THE AMERICAN SOCIETY FOR MOHS SURGERY

The next step is to apply a sterile cotton ball and cover the dressing with bio-occlusive tape for 24 hours – the time it takes the paste to achieve full penetration. After 24 hours, the patient can return for a conventional, wide excision with standard vertical or bevelled Mohs margins, followed by closure.

However, to take advantage of the paste's immunologic properties, the block of tissue should be left in place for a week or longer, or the main block can be removed, leaving a rim of the fixed tissue in place to stimulate the immune response. Dr. Brooks said the fixed tissue can then be histologically examined to confirm negative margins. For patients with raised lesions, he recommended debulking to create a flat tissue plane and they applying the paste as described.

He also stressed that the Mohs paste does not interfere in any way with conventional melanoma treatment. "About half of my patients end up going to [a cancer center] for excision, sentinel nodes, or other treatment," including interferon, he said. But some patients, after reviewing the comparatively small survival benefit interferon offers and its significant side effects, elect to have the fixed tissue excised and then continue with the practice of node palpation and regular ultrasounds to identify any early disease spread.

Dr. Brooks reported having no relevant financial disclosures.

Pages

Recommended Reading

Sunscreens Don't Always Live Up to Advertising Promises
MDedge Dermatology
FDA Postpones Ipilumimab Review
MDedge Dermatology
Benefits of BRAF Inhibitor Confirmed in Metastatic Melanoma
MDedge Dermatology
Making a Neurofibromatosis Type 1 Diagnosis: Check the Armpits!
MDedge Dermatology
NIH at Forefront of New Clinical Trials Push, Director Says
MDedge Dermatology
Primary Care Physicians Performing More Skin Cancer Screenings
MDedge Dermatology
Can Bundled Cancer-Care Payments Save a Bundle?
MDedge Dermatology
FDA Committee Considers Gardasil for Anal Cancer Prevention
MDedge Dermatology
FDA Panel Divided on MelaFind Device
MDedge Dermatology
PV-10 Melanoma Drug Trial Enrolls Patients in Compassionate Use Program
MDedge Dermatology